Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
NCT02374489 · National Health Research Institutes, Taiwan · PHASE2 · terminated · last registry update 2018-04-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “ROS1 in IHC and gene rearrangement result can not match。No tumor response。” | – | Registry record, National Health Research Institutes, Taiwan |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-03-14Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Crizotinib (NCT03874273)
- 2019-02-12Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT01685138)
- 2019-01-25Results posted on the registry: Pfizer, PF-06463922 + rifampin (NCT02804399)
- 2019-01-17Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT02040870)
- 2018-12-21Phase 3 first posted: Institut National de la Santé Et de la Recherche Médicale, France, Nilotinib + Ceritinib (NCT03784014)
- 2018-12-07Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT03768063)
- 2018-10-25Results posted on the registry: Pfizer, crizotinib + crizotinib (NCT01576406)
- 2018-08-24Results posted on the registry: Hoffmann-La Roche, Alectinib (NCT02621047)
- 2018-08-21Results posted on the registry: Ludwig Institute for Cancer Research, Ensartinib + Durvalumab (NCT02898116)
- 2018-07-24Phase 3 first posted: Takeda, Brigatinib + Alectinib (NCT03596866)
- 2018-05-29Results posted on the registry: Pfizer, PF-06463922 + Crizotinib (NCT01970865)
- 2018-04-02Also stopped (terminated): Criterium, Inc., ceritinib (NCT02638909)
- 2018-03-15Results posted on the registry: Hoffmann-La Roche, Alectinib + Crizotinib (NCT02075840)
- 2018-03-07Phase 3 first posted: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2018-02-26Results posted on the registry: Hoffmann-La Roche, Alectinib + Docetaxel (NCT02604342)
- 2017-09-21Results posted on the registry: Novartis Pharmaceuticals, Ceritinib + Pemetrexed (NCT01828099)
- 2017-08-09Also stopped (terminated): Mothaffar Rimawi, Crixotinib 200 mg and Sunitinib Cohort 1 + Crixotinib 250 mg and Sunitinib Cohort 2 (NCT02074878)
- 2017-07-27Results posted on the registry: Novartis Pharmaceuticals, Ceritinib + Pemetrexed (NCT01828112)
- 2017-06-21Phase 3 first posted: Hoffmann-La Roche, Alectinib + Crizotinib (NCT03194893)
- 2017-06-21Results posted on the registry: Ariad Pharmaceuticals, Brigatinib (NCT01449461)
- 2017-06-21Results posted on the registry: Ariad Pharmaceuticals, Brigatinib (NCT02094573)
- 2017-06-07Phase 3 first posted: Hoffmann-La Roche, Alectinib + Atezolizumab (NCT03178552)
- 2017-05-08Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT01685060)
- 2017-04-25Phase 3 first posted: Children's Oncology Group, Busulfan + Carboplatin (NCT03126916)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision